BFM
TPST icon

Boothbay Fund Management’s Tempest Therapeutics TPST Stock Holding History

Boothbay Fund Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5
Closed -$519K – 1112
2020
Q1 		$519K Buy
+5
New +$7.29K 0.04% 456

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's TPST Position: Q1 2025 in Review

Boothbay Fund Management sold out of Tempest Therapeutics (TPST) in Q1 2025, closing a stake of 1,866 shares — an estimated $20.2K sold.

Boothbay Fund Management first reported a position in TPST in Q2 2020 and held it in 10 quarters. The position peaked at $189K in Q1 2021. 23 funds tracked by Wall St. Rank hold TPST as of Q1 2025.

  • Boothbay Fund Management reported no remaining Tempest Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 1,866 Tempest Therapeutics shares in Q1 2025, an estimated $20.2K.
  • Boothbay Fund Management first reported a position in Tempest Therapeutics in Q2 2020 and held it in 10 quarters.
  • Boothbay Fund Management's Tempest Therapeutics position peaked at $189K in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.